Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply?

Abstract

BackgroundFaecal calprotectin (FC), a cytosolic protein released by neutrophils (S100 family) in response to inflammation, is a simple, non-invasive test that can be used to differentiate irritable bowel syndrome (IBS) with inflammatory bowel disease (IBD), where there can be considerable symptom overlap.Aims and methodsThe aims of the study were (1) to be able to predict the ability of FC to exclude IBD and determine cut-offs when in remission, (2) to investigate the effects of time and temperature on stability of FC and (3) compare three ELISA kits to measure FC: Buhlmann, PhiCal v1 and PhiCal v2. A total of 311 patients with altered bowel habit were tested for FC; 144 with IBS, 148 with IBD and 19 with other organic causes.ResultsSensitivity and specificity of FC (with PhiCal v2 kit) to distinguish between functional disorder (IBS) and IBD using cut-off 50 μg/g were 88% and 78%, respectively, with a negative predictive value of 87%. Area under the receiver operating curve was 0.84 (CI 0.78 to 0.90). For those with IBD, FC values below 250 μg/g corresponded with remission of disease with a sensitivity and specificity of 90% and 76%, respectively. Area under the receiver operating curve was 0.93 (CI 0.89 to 0.97). FC was stable once extracted and frozen for up to 2.5 months. Pearson correlation was good between Buhlmann assay and PhiCal v2 (r2 = 0.95).ConclusionsFC has up to 87% negative predictive value to exclude IBD, and cut-offs less than 250 μg/g had 90% sensitivity to determine remission in IBD. Once frozen, FC is stable and the ELISA monoclonal plates were broadly comparable.

Association Between Fecal Calprotectin Levels and Small-bowel Inflammation Score in Capsule Endoscopy: A Multicenter Retrospective Study

“…Currently, healthcare systems worldwide are under significant economic strain to provide high-quality care with shrivelling budgets [26,27]. Therefore, increasing the diagnostic yield of patient workup with inexpensive, accurate, non-invasive investigations, has multiple benefits [13,28].…”

A double‐blind, placebo‐controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea‐predominant IBS

“…Fecal calprotectin was expressed as μg g −1 of feces. Normal values are in the range of 0‐50 μg g −1 and values of 50‐100 μg g −1 are considered borderline for intestinal inflammation …”

Fecal Calprotectin and serum chromogranin A as potential biomarkers of irritable bowel syndrome symptom severity

“…One of the most promising fecal biomarkers is Calprotectin, a neutrophil derived protein which has been useful as a marker for inflammatory bowel disease (IBD) [20,21]. Fecal Calprotectin (FC) accounts for about 60% of the soluble proteins in the cytosol fraction of neutrophil granulocytes.…”